The Clinical Impact of 21-Gene Recurrence Score on Treatment Decisions for Patients with Hormone Receptor-Positive Early Breast Cancer in Korea
Moo Hyun Lee, Wonshik Han, Jeong Eon Lee, Ku Sang Kim, Heeseung Park, Jongjin Kim, Soo Youn Bae, Hyun Joo Shin, Jong Won Lee, Eun Sook Lee
Cancer Res Treat. 2015;47(2):208-214.   Published online 2014 Sep 11     DOI:
Citations to this article as recorded by Crossref logo
The Rochester Modified Magee Algorithm (RoMMa): An Outcomes Based Strategy for Clinical Risk-Assessment and Risk-Stratification in ER Positive, HER2 Negative Breast Cancer Patients Being Considered for Oncotype DX® Testing
Bradley M. Turner, Brian S. Finkelman, David G. Hicks, Numbere Numbereye, Ioana Moisini, Ajay Dhakal, Kristin Skinner, Mary Ann G. Sanders, Xi Wang, Michelle Shayne, Linda Schiffhauer, Hani Katerji, Huina Zhang
Cancers.2023; 15(3): 903.     CrossRef
Comprehensive analysis of the 21-gene recurrence score in invasive ductal breast carcinoma with or without ductal carcinoma in situ component
Yufei Zeng, Weiqi Gao, Xiaosong Chen, Kunwei Shen
British Journal of Cancer.2021; 124(5): 975.     CrossRef
Identifying Clinicopathological Factors Associated with Oncotype DX® 21-Gene Recurrence Score: A Real-World Retrospective Cohort Study of Breast Cancer Patients in Quebec City, Canada
Simon Gagnet, Caroline Diorio, Louise Provencher, Cynthia Mbuya-Bienge, Julie Lapointe, Claudya Morin, Julie Lemieux, Hermann Nabi
Journal of Personalized Medicine.2021; 11(9): 858.     CrossRef
Biomarker and multigene assay testing in ER positive, HER-2 negative breast carcinomas: An international guidelines-based approach
Bradley M. Turner, Hani Katerji, Huina Zhang, David G. Hicks
Human Pathology Reports.2021; 26: 300574.     CrossRef
Development of a Nomogram to Predict the Recurrence Score of 21-Gene Prediction Assay in Hormone Receptor–Positive Early Breast Cancer
Shin Hye Yoo, Tae-Yong Kim, Miso Kim, Kyung-Hun Lee, Eunshin Lee, Han-Byoel Lee, Hyeong-Gon Moon, Wonshik Han, Dong-Young Noh, Sae-Won Han, Tae-You Kim, Seock-Ah Im
Clinical Breast Cancer.2020; 20(2): 98.     CrossRef
Impact of 21-gene recurrence score testing on adjuvant chemotherapy decision making in older patients with breast cancer
Yufei Zeng, Weiqi Gao, Lin Lin, Xiaosong Chen, Kunwei Shen
Journal of Geriatric Oncology.2020; 11(5): 843.     CrossRef
Prognostic Factors of Disease Recurrence in Breast Cancer Using Quantitative and Qualitative Magnetic Resonance Imaging (MRI) Parameters
Jeongmin Lee, Sung Hun Kim, Bong Joo Kang
Scientific Reports.2020;[Epub]     CrossRef
The impact of the 21-gene recurrence score (Oncotype DX) on concordance of adjuvant therapy decision making as measured by the Liverpool Systemic Therapy Adjuvant Decision Tool
Anna Olsson-Brown, Pavlos Piskilidis, Julie O'Hagan, Nicky Thorp, Peter Robson, Helen Innes, Helen Wong, Silvia Cicconi, Richard Jackson, Tamara Kiernan, Christopher Holcombe, Susan O'Reilly, Carlo Palmieri
The Breast.2019; 44: 94.     CrossRef
Clinical significance of 21-gene recurrence score assay for hormone receptor–positive, lymph node-negative breast cancer in early stage
Yang Yu-qing, Wang Lei, Huang Mei-ling, Xiao Jing-jing, Wei Mei-chen, Wu Jiang, Hao Jun-sheng, Ling Rui, Li Nan-lin
Experimental and Molecular Pathology.2019; 108: 150.     CrossRef
Tumour profiling tests to guide adjuvant chemotherapy decisions in early breast cancer: a systematic review and economic analysis
Sue Harnan, Paul Tappenden, Katy Cooper, John Stevens, Alice Bessey, Rachid Rafia, Sue Ward, Ruth Wong, Robert C Stein, Janet Brown
Health Technology Assessment.2019; 23(30): 1.     CrossRef
Uptake of the 21-Gene Assay Among Women With Node-Positive, Hormone Receptor−Positive Breast Cancer
Megan C. Roberts, Allison W. Kurian, Valentina I. Petkov
Journal of the National Comprehensive Cancer Network.2019; 17(6): 662.     CrossRef
Adjuvant chemotherapy and survival among patients 70 years of age and younger with node-negative breast cancer and the 21-gene recurrence score of 26–30
Seho Park, Yunan Han, Ying Liu, Adetunji T. Toriola, Lindsay L. Peterson, Graham A. Colditz, Seung Il Kim, Young Up Cho, Byeong-Woo Park, Yikyung Park
Breast Cancer Research.2019;[Epub]     CrossRef
Clinical analysis of 21‑gene recurrence score test in hormone receptor‑positive early‑stage breast cancer
Lizhe Zhu, Nan Ma, Bin Wang, Can Zhou, Yu Yan, Ke Wang, Jianjun He, Yu Ren
Oncology Letters.2019;[Epub]     CrossRef
Systematic review of the clinical and economic value of gene expression profiles for invasive early breast cancer available in Europe
E.J. Blok, E. Bastiaannet, W.B. van den Hout, G.J. Liefers, V.T.H.B.M. Smit, J.R. Kroep, C.J.H. van de Velde
Cancer Treatment Reviews.2018; 62: 74.     CrossRef
Verification of a Western Nomogram for Predicting Oncotype DX™ Recurrence Scores in Korean Patients with Breast Cancer
Jae-Myung Kim, Jai Min Ryu, Isaac Kim, Hee Jun Choi, Seok Jin Nam, Seok Won Kim, Jonghan Yu, Se Kyung Lee, Jeong Eon Lee
Journal of Breast Cancer.2018; 21(2): 222.     CrossRef
Use of adjuvant chemotherapy in hormone receptor-positive breast cancer patients with or without the 21-gene expression assay
Soo Jin Park, Moo Hyun Lee, Sun-Young Kong, Mi Kyung Song, Jungnam Joo, Youngmee Kwon, Eun-Gyeong Lee, Jai Hong Han, Sung Hoon Sim, So-Youn Jung, Seeyoun Lee, Keun Seok Lee, In Hae Park, Eun Sook Lee
Breast Cancer Research and Treatment.2018; 170(1): 69.     CrossRef
Practice patterns and outcomes for patients with node-negative hormone receptor-positive breast cancer and intermediate 21-gene Recurrence Scores
Jonathan Chen, Xian Wu, Paul J. Christos, Silvia Formenti, Himanshu Nagar
Breast Cancer Research.2018;[Epub]     CrossRef
Only estrogen receptor “positive” is not enough to predict the prognosis of breast cancer
Jai Min Ryu, Hee Jun Choi, Isaac Kim, Se Kyung Lee, Jonghan Yu, Jee-Eun Kim, Byeong-il Kang, Jeong Eon Lee, Seok Jin Nam, Seok Won Kim
Breast Cancer Research and Treatment.2018; 172(3): 627.     CrossRef
Examination of the Biomark assay as an alternative to Oncotype DX for defining chemotherapy benefit
Jinkyoung Kim, Aeree Kim, Chungyeul Kim
Oncology Letters.2018;[Epub]     CrossRef
Impact d’un test de signature génomique en sénologie sur les décisions en réunion de concertation pluridisciplinaire : une expérience française
C. Dreyfus, M. Ballester, J. Gligorov, P. Agranat, M. Antoine, I. Tengher, A. Bricou
Gynécologie Obstétrique & Fertilité.2015; 43(12): 780.     CrossRef